QurientQurient

팝업레이어 알림

팝업레이어 알림이 없습니다.

최신글

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

  • Notice

      2025-03-27
      주식회사 큐리언트 제17기 결산공고
      2025-03-14
      신주발행공고
      2025-03-11
      제17기 정기주주총회 소집통지 공고
      2024-12-17
      『바이오테크 익스프레스: 혁신 신약을 찾아서』출간 안내
      2024-03-04
      큐리언트 기업설명회 IR 자료 공지
  • Press Release

      2025-04-01
      큐리언트, 텔라세벡 결핵 임상 2A상 최종 결과 논문 발표
      2025-03-26
      큐리언트 '텔라세벡', WHO 글로벌 회의서 임상 중간결과 발표
      2025-03-14
      큐리언트, 동구바이오제약 대상 80억 규모 유증
      2025-02-21
      큐리언트, 백혈병 임상 첫 환자 투약…1차 치료제 도약 기대
      2025-01-02
      큐리언트, 만성 이식편대숙주질환 美 임상 IND 승인
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file